US Broker Ratings

Tyra Biosciences, Inc. (TYRA) Stock Analysis: A Biotech with 57% Potential Upside

Tyra Biosciences, Inc. (NASDAQ: TYRA), a clinical-stage biotechnology firm, is capturing the attention of investors with its notable potential upside of 57.33%, according to analyst ratings. With a market capitalization..

Celcuity Inc. (CELC) Stock Analysis: Biotechnology Innovator’s 9.29% Upside Captures Investor Attention

Celcuity Inc. (NASDAQ: CELC), a clinical-stage biotechnology company, is making waves in the healthcare sector with its innovative approach to cancer treatment. With a market capitalization of $4.94 billion, Celcuity..

AnaptysBio, Inc. (ANAB) Investor Outlook: Analyzing a 22.46% Potential Upside with Strong Buy Ratings

AnaptysBio, Inc. (NASDAQ: ANAB), a clinical-stage biotechnology company headquartered in San Diego, California, is capturing investor attention with an enticing 22.46% potential upside, as indicated by the latest analyst ratings...

Bioventus Inc. (BVS) Investor Outlook: A 69% Potential Upside and Strong Analyst Ratings

Bioventus Inc. (NASDAQ: BVS), a prominent player in the healthcare sector, specifically within the medical devices industry, has caught the eye of investors with a robust potential upside of 69%..

Kura Oncology, Inc. (KURA): Investor Outlook with a Promising 278% Potential Upside

Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company based in San Diego, California, is gaining significant attention from investors with its potential for substantial upside. As a key player..

Trevi Therapeutics, Inc. (TRVI) Stock Analysis: Unpacking the 104% Potential Upside

Trevi Therapeutics, Inc. (NASDAQ: TRVI) emerges as a compelling player in the biotechnology sector with its focus on pioneering treatments for chronic cough and pruritus. The company, headquartered in New..

Prothena Corporation plc (PRTA) Stock Analysis: A 125% Upside Potential in the Biotech Sector?

Investors eyeing the biotechnology sector may find Prothena Corporation plc (NASDAQ: PRTA) a compelling prospect, thanks to its significant upside potential and thriving pipeline in neurodegenerative disease therapeutics. Based in..

Verastem, Inc. (VSTM) Stock Analysis: Navigating the 179% Potential Upside in the Biotech Sector

For investors with a keen eye on biotechnology stocks, Verastem, Inc. (NASDAQ: VSTM) presents a particularly intriguing opportunity within the healthcare sector. With a market capitalization of $447.4 million, this..

Rocket Pharmaceuticals, Inc. (RCKT) Stock Analysis: Exploring a 104.55% Potential Upside in Gene Therapy Innovations

Rocket Pharmaceuticals, Inc. (RCKT) is a promising player in the biotechnology sector, focusing on the development of transformative gene therapies for rare and devastating diseases. With a market capitalization of..

Orthofix Medical Inc. (OFIX) Stock Analysis: A 41.61% Potential Upside for Investors in the Medical Device Sector

Orthofix Medical Inc. (NASDAQ: OFIX), a key player in the healthcare sector specializing in medical devices, presents a compelling opportunity for investors eyeing growth in the medical technology space. With..

AtaiBeckley Inc. (ATAI): Biotech Disruptor with a Promising 226% Upside Amid Mental Health Breakthroughs

AtaiBeckley Inc. (NASDAQ: ATAI), a rising star in the biotechnology sector, is capturing investor attention with its groundbreaking approach to mental health treatments. Specializing in the research and development of..

Personalis, Inc. (PSNL) Stock Analysis: A 26.66% Potential Upside Amidst Strategic Collaborations in Cancer Genomics

Personalis, Inc. (PSNL), a prominent player in the healthcare sector’s diagnostics and research industry, is gaining attention for its innovative cancer genomic tests and services. With a market cap of..

Humacyte, Inc. (HUMA) Stock Analysis: Unpacking a 570% Potential Upside

Humacyte, Inc. (NASDAQ: HUMA), a burgeoning player in the biotechnology sector, has captured the attention of investors with its innovative approach to healthcare solutions. Specializing in bioengineered human tissues, Humacyte..

Precigen, Inc. (PGEN): Investor Outlook on a Biotech with 88% Potential Upside

Precigen, Inc. (NASDAQ: PGEN) has recently captured the attention of investors due to its significant growth potential within the biotechnology sector. The company, headquartered in Germantown, Maryland, is at the..

AbCellera Biologics Inc. (ABCL) Investor Outlook: Potential Upside of 205% Amidst Biotech Innovations

AbCellera Biologics Inc. (NASDAQ: ABCL), a prominent player in the biotechnology sector, is making waves with its robust pipeline of antibody-based medicines developed to address unmet medical needs. Headquartered in..

Cel-Sci Corporation (CVM) Stock Analysis: Exploring a Potential 778% Upside for Biotech Investors

Cel-Sci Corporation (NASDAQ: CVM), a clinical-stage biotechnology company, has captured the attention of investors with its promising immunotherapy developments and impressive potential upside. With a market capitalization of $40.7 million,..

REGENXBIO Inc. (RGNX) Stock Analysis: Examining a 238% Potential Upside in the Biotech Sector

For investors hunting for opportunities in the healthcare sector, REGENXBIO Inc. (NASDAQ: RGNX) presents a compelling case with its strong potential upside. The biotechnology company, headquartered in Rockville, Maryland, focuses..

Bicycle Therapeutics plc (BCYC) Stock Analysis: Unpacking Its 239% Potential Upside

Bicycle Therapeutics plc (NASDAQ: BCYC), a clinical-stage pharmaceutical innovator, is capturing attention with its ambitious pipeline and robust analyst backing. With a potential upside of 239.35%, BCYC has become an..

Tectonic Therapeutic, Inc. (TECX) Stock Analysis: Exploring a 278% Potential Upside

For investors venturing into the dynamic landscape of biotechnology, Tectonic Therapeutic, Inc. (NASDAQ: TECX) presents a compelling opportunity characterized by innovation and substantial growth potential. With its focus on developing..

Septerna, Inc. (SEPN) Stock Analysis: A Biotech Powerhouse with a 25% Upside Potential

Septerna, Inc. (NASDAQ: SEPN) is capturing the attention of investors in the healthcare sector with its significant growth potential and innovative contributions to biotechnology. As a clinical-stage company specializing in..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds